


CLAIMS

1. A quinazoline derivative of the Formula I:



5 wherein **n** is 0, 1, 2 or 3,

each **R**⁵ is independently selected from halogeno, cyano, nitro, hydroxy, amino, carboxy, sulfamoyl, trifluoromethyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,

10 N-(1-6C)alkylsulfamoyl, and N,N-di-[(1-6C)alkyl]sulfamoyl, C(O)NR⁶R⁷ where R⁶ and R⁷ are independently selected from hydrogen, optionally substituted (1-6C)alkyl, optionally substituted (3-8C)cycloalkyl or optionally substituted aryl, or R⁶ and R⁷ together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring which may contain additional heteroatoms;

15 X¹ is a direct bond or O;

R¹ is selected from hydrogen and (1-6C)alkyl, wherein the (1-6C)alkyl group is optionally substituted by one or more substituents, which may be the same or different, selected from hydroxy and halogeno, and/or a substituent selected from amino, nitro, carboxy, cyano, halogeno, (1-6C)alkoxy, hydroxy(1-6C)alkoxy, (2-8C)alkenyl, (2-8C)alkynyl,

20 (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, carbamoyl, N-(1-6C)alkylcarbamoyl, N,N di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl, sulfamoyl, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and

25 N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;

m is 0, 1, 2 or 3;

R² is hydrogen or (1-6C)alkyl; and

R³ is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or (1-6C)alkoxy, any of which can be optionally substituted on a carbon atom by a (1-6C)alkoxy, amino, (1-6C)alkylamino,

di-(1-6C)alkylamino, or a group S(O)_s(1-6C)alkyl where s is 0, 1 or 2, or a saturated 5 or 6 membered heterocyclic ring which optionally contains additional heteroatoms selected from oxygen, sulfur or NR⁸ where R⁸ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkylsulfonyl or (1-6C)alkylcarbonyl;

or R² and R³ together with the nitrogen atom to which they are attached form a saturated 5 or 6 membered heterocyclic ring which optionally contains additional heteroatoms selected from

10 oxygen, S, SO or S(O)₂ or NR⁸ where R⁸ is as defined above;

provided that the quinazoline derivative is not:

4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(dimethylamino)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;

15 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yl-oxy}-quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(dimethylamino)carbonyl]-piperidin-4-yl-oxy}-quinazoline;

20 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(diethylamino)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(piperidin-1-yl)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;

25 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(pyrrolidin-1-yl)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(4-methyl-piperazin-1-yl)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yl-oxy}-7-ethoxy-quinazoline;

30 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yl-oxy}-7-(2-methoxy-ethoxy)-quinazoline;

4-[(3-ethynyl-phenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;


- 69 -

- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(ethylamino)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(isopropylamino)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 5 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(dimethylamino)carbonylmethyl]-piperidin-4-yl-oxy}-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(morpholin-4-yl)carbonylmethyl]-piperidin-4-yl-oxy}-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(dimethylamino)carbonylmethyl]-10 piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(morpholin-4-yl)carbonylmethyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(methylamino)carbonylmethyl]-15 piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(pyrrolidin-1-yl)carbonylmethyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(morpholin-4-yl)carbonylmethyl]-20 piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(methylamino)carbonyl]-piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(2-methoxyethyl)amino]carbonyl}-25 piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(N-methyl-N-2-methoxyethyl)amino]carbonyl}-piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(3-methoxypropyl)amino]carbonyl}-30 piperidin-4-yl-oxy}-7-methoxy-quinazoline;
- 4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(N-methyl-N-3-methoxypropyl)amino]carbonyl}-piperidin-4-yl-oxy}-7-methoxy-quinazoline; or

- 70 -


4-[(3-chloro-4-fluorophenyl)amino]-6-{1-[(morpholin-4-yl)carbonyl]propyl}-
piperidin-4-yl-oxy}-7-methoxy-quinazoline;
or a pharmaceutically acceptable salt thereof.

- 5 2. A quinazoline derivative according to claim 1, wherein n is 1, 2 or 3.
3. A quinazoline derivative according to claim 1 or claim 2, wherein n is 2 or 3.
4. A quinazoline derivative according to any one of claims 1 to 3, wherein n is 2.
10
5. A quinazoline derivative according to any one of claims 1 to 3, wherein n is 3.
6. A quinazoline derivative according to any one of the preceding claims, wherein each
group R⁵ is a halogeno group.
15
7. A quinazoline derivative according to any one of the preceding claims, wherein each
group R⁵ is selected from chloro and fluoro.
8. A quinazoline derivative according to any one of the preceding claims, which includes
20 a group R⁵ positioned at an ortho- (2-) position on the benzene ring to which it is attached.
9. A quinazoline derivative according to claim 8, wherein the group R⁵ positioned at the
ortho- (2-) position is fluoro.
- 25 10. A quinazoline derivative according to any one of the preceding claims, wherein in the
Formula I, the group of sub-formula (i):



is a group of sub-formula (ii):

- 71 -



wherein (a) one of R¹⁰ or R¹² is hydrogen and the other is halogeno, and R¹¹ is halogeno, or
 (b) R¹⁰ is halogeno, R¹¹ is halogeno and R¹² is selected from hydrogen or halogeno, or (c) R¹⁰
 is fluoro, R¹¹ is chloro, and R¹² is selected hydrogen or fluoro.

5

11. A quinazoline derivative according to claim 10, wherein one of R¹⁰ or R¹² is hydrogen and the other is fluoro, and R¹¹ is chloro.

10 12. A quinazoline derivative according to claim 10, wherein R¹⁰ is fluoro, R¹¹ is chloro, and R¹² is hydrogen.

13. A quinazoline derivative according to claim 10, wherein R¹⁰ is fluoro, R¹¹ is chloro, and R¹² is fluoro.

15 14. A quinazoline derivative according to any one of the preceding claims, wherein X¹ is oxygen.

15. A quinazoline derivative according to any one of the preceding claims, wherein R¹ is selected from hydrogen, (1-6C)alkyl and (1-6C)alkoxy(1-6C)alkyl, wherein any (1-6C)alkyl group in R¹ optionally bears one or more hydroxy or halogeno substituents


20 16. A quinazoline derivative according to claim 15, wherein R¹ is selected from (1-6C)alkyl, which optionally bears one or more hydroxy or halogeno substituents.

25 17. A quinazoline derivative according to any one of the claims 1 to 13, wherein R¹-X¹- is selected from hydrogen, methoxy, ethoxy and 2-methoxyethoxy.

18. A quinazoline derivative according to claim 17, wherein R¹-X¹- is methoxy.

- 72 -


19. A quinazoline derivative according to claim 1 of Formula IA:



wherein R^2 , R^3 and m are as defined in claim 1, R^{10} , R^{11} and R^{12} are as defined in any one of claims 10 to 13, and R^{13} is selected from hydrogen, methoxy, ethoxy and 2-methoxyethoxy.

5

20. A quinazoline derivative according to claim 1 of Formula IB:




IB

wherein R^2 , R^3 and m are as defined in claim 1 and R^{13} is selected from hydrogen, methoxy, ethoxy and 2-methoxyethoxy.

10

21. A quinazoline derivative according to claim 1 of Formula IC:



IC

- 73 -

wherein R², R³ and m are as defined in claim 1 and R¹³ is selected from hydrogen, methoxy, ethoxy and 2-methoxyethoxy.

22. A quinazoline derivative according to any one of claims 19 to 21, wherein R¹³ is
5 methoxy.

23. A quinazoline derivative according to any one of the preceding claims, wherein m is 0 or 1.

10 24. A quinazoline derivative according to any one of the preceding claims, wherein m is 1.

25. A quinazoline derivative according to any one of the preceding claims, wherein R² is hydrogen or (1-3C)alkyl.

15 26. A quinazoline derivative according to any one of the preceding claims, wherein R² is hydrogen or methyl.

27. A quinazoline derivative according to any one of the preceding claims, wherein R² is hydrogen.

20 28. A quinazoline derivative according to any one of the preceding claims, wherein R³ is (1-6C)alkyl.

25 29. A quinazoline derivative according to any one of the preceding claims, wherein R³ is (1-3C)alkyl.

30. A quinazoline derivative according to any one of the preceding claims, wherein R³ is methyl.

30 31. A quinazoline derivative according to claim 1, which is selected from one or more of the following:


4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy}quinazoline;

- 4-(3-chloro-2-fluoroanilino)-6-{{[1-(N,N-dimethylcarbamoylmethyl)piperidin-4-yl]oxy}-7-methoxyquinazoline;
- 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-(morpholin-4-ylcarbonylmethyl)piperidin-4-yl]oxy}- quinazoline;
- 5 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-(pyrrolidin-1-ylcarbonyl)piperidin-4-yl]oxy} quinazoline;
- 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-(N-methylcarbamoyl)piperidin-4-yl]oxy} quinazoline;
- 4-(3-chloro-2-fluoroanilino)-6-{{[1-(N-(2-dimethylaminoethyl)carbamoyl)piperidin-4-yl]oxy}-
- 10 7-methoxyquinazoline;
- 4-(3-chloro-2-fluoroanilino)-6-{{[1-(N,N-dimethylcarbamoyl)piperidin-4-yl]oxy}7-methoxy-q
uinazoline;
- 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-(morpholin-4-ylcarbonyl)piperidin-4-yl]oxy} quinazoline;
- 15 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-(N-[2-pyrrolidin-1-ylethyl]carbamoyl)
piperidin-4-yl]oxy}quinazoline;
- 4-(3-chloro-2,4-difluoroanilino)-7-methoxy-6-{{[1-(N-methylcarbamoylmethyl)piperidin-4-
yl]oxy}quinazoline;
- 4-(3-chloro-2-fluoroanilino)-6-{{[1-(N-ethylcarbamoylmethyl)piperidin-4-yl]oxy}-7-
- 20 methoxyquinazoline;
- 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-(N-[2-(pyrrolidin-1-
yl)ethyl]carbamoylmethyl)piperidin-4-yl]oxy}quinazoline;
- 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-(N-(2-
methoxethyl)carbamoylmethyl)piperidin-4-yl]oxy}quinazoline;
- 25 4-(3-chloro-2-fluoroanilino)-6-{{[1-(N-(2-dimethylaminoethyl)carbamoylmethyl)piperidin-4-
yl]oxy}-7-methoxyquinazoline;
- 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-[2-(4-methylpiperazin-1-yl)-2-
oxoethyl)piperidin-4-yl]oxy}quinazoline;
- 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{{[1-[2-(piperazin-1-yl)-2-oxoethyl)piperidin-4-
30 yl]oxy}quinazoline; and
- 4-(3-chloro-2,4-difluoroanilino)-7-methoxy-6-{{[1-[2-(4-methylpiperazin-1-yl)-2-
oxoethyl)piperidin-4-yl]oxy}quinazoline;
or a pharmaceutically acceptable salt thereof.

- 75 -

32. A process for preparing a quinazoline derivative according to any one of the preceding claims, which comprises either


Process (a) reacting a compound of the Formula II:



II

5 wherein R¹, X¹, R⁵ and n have any of the meanings defined in claim 1 except that any functional group is protected if necessary,

with a compound of the Formula III:




wherein R², R³ and m have any of the meanings defined in claim 1 except that any functional group is protected if necessary and Lg is a displaceable group, wherein the reaction is conveniently performed in the presence of a suitable base,

Process (b) modifying a substituent in or introducing a substituent into another quinazoline derivative of Formula I or a pharmaceutically acceptable salt thereof, as hereinbefore defined except that any functional group is protected if necessary;



15 **Process (c)** reacting a compound of Formula IV:

- 76 -



IV

where R^1 , X^1 , R^5 and n are as defined in relation to Formula I except that any functional group is protected if necessary, with a compound of the Formula V or V':



- 5 wherein R^2 and R^3 are as defined above and m' is 0, 1, 2 or 3, provided that it is not 0 when R^2 is hydrogen, and Lg is a displaceable group;


Process (d) removal of a protecting group from a quinazoline derivative of Formula I, or a pharmaceutically acceptable salt thereof;

- 10 **Process (e)** reacting a compound of the Formula II as hereinbefore defined with a compound of the Formula III as defined hereinbefore except Lg is OH under Mitsunobu conditions;

Process (f) for the preparation of those compounds of the Formula I wherein R^1-X^1 is a hydroxy group, cleavage of a quinazoline derivative of the Formula I wherein R^1-X^1 is a (1-6C)alkoxy group;

- 15 **Process (g)** for the preparation of those compounds of the Formula I wherein X^1 is O and R^1 is not hydrogen, by the reaction of a compound of the Formula VI:


- 77 -



VI

wherein R², R³, R⁵, m and n have any of the meanings defined in claim 1 except that any functional group is protected if necessary, with a compound of the formula R¹-Lg, wherein R¹ has any of the meanings defined in claim 1 except that it is not hydrogen and except that any functional group is protected if necessary and Lg is a displaceable group;

- Process (h)** for the preparation of those compounds of the Formula I wherein R¹ contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, alkylation of a quinazoline derivative of the Formula I wherein or R¹ contains a hydroxy group or a primary or secondary amino group as appropriate;
- 10 Process (i)** for the preparation of those compounds of the Formula I wherein R¹ is substituted by a group T, wherein T is selected from (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoylamino, (1-6C)alkylthio, (1-6C)alkylsulfinyl and (1-6C)alkylsulfonyl, the reaction of a compound of the Formula VII:




VII

- 15** wherein R², R³, R⁵, X¹, n and m have any of the meanings defined hereinbefore except that any functional group is protected if necessary, R^{1'} is a group R¹ as defined herein except that any T groups are replaced with Lg, and Lg is a displaceable group (for example chloro or bromo) with a compound of the formula TH, wherein T is as defined above except that any functional group is protected if necessary;

- 78 -

Process (j) reacting a compound of the Formula VIII:




VIII

wherein R^1 , R^2 , R^3 , X^1 , and m have any of the meanings defined in claim 1 except that any functional group is protected if necessary and Lg is a displaceable group as hereinbefore

5 defined,


with an aniline of the Formula IX:



IX

wherein R^5 and n have any of the meanings defined in claim 1 except that any functional group is protected if necessary, and wherein the reaction is conveniently performed in the
10 presence of a suitable acid;

Process (k) for the preparation of those compounds of the Formula I wherein m is 1, 2 or 3, coupling of a compound of Formula X:




X

wherein m is 1, 2 or 3 and R^1 , X^1 , R^3 , and n are as hereinbefore defined in claim 1, except
15 any functional group is protected if necessary, with a primary or secondary amine of formula R^2NHR^3 where R^2 and R^3 are as defined in claim 1;


- 79 -

Process (l) By reacting a compound of Formula IV as defined above except that any functional group is protected if necessary, with a compound of the Formula V'':



using a reductive amination procedure,

- 5 **Process (m)** for the preparation of those compounds of the Formula I wherein R^3 is (2-6C)alkyl substituted on a carbon atom by an amino, (1-6C)alkylamino, di-(1-6C)alkylamino or a saturated 5 or 6 membered heterocyclic ring which contains NR^8 where R^8 is as defined in claim 1, by reacting a compound of the Formula XX:



XX

- 10 wherein R^{3a} is Lg -(2-6C)alkyl, wherein Lg is a displaceable group and wherein R^1 , R^2 , X^1 , R^5 , m and n have any of the meanings defined hereinbefore except that any functional group is protected if necessary,
with ammonia or with a suitable primary or secondary amine,
and whereafter any of said processes, any protecting group that is present is removed.

15

33. A pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined in any one of claims 1 to 31 in association with a pharmaceutically-acceptable diluent or carrier.

- 20 34. A quinazoline derivative of the Formula I as defined in any one of claims 1 to 31, or a pharmaceutically acceptable salt thereof, for use as a medicament.

- 80 -

35. The use of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined in any one of claims 1 to 31 in the manufacture of a medicament for use in the production of an anti-proliferative effect in a warm-blooded animal.
- 5 36. A method for producing an anti-proliferative effect in a warm-blooded animal in need of such treatment which comprises administering to said animal a quinazoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, as defined any one of claims 1 to 31.
- 10 37. A compound of the Formula VI, VII, VIII, X or XX as defined in claim 32 or a salt thereof.